COVID Vaccine-Induced Myocarditis Cited by Medical Examiners in Death of Two Boys
Two adolescent boys, who suddenly passed away in Connecticut and Michigan within a week after receiving the second dose of Pfizer/BioNTech’s BNT162b2 (also known as “Comirnaty”) messenger RNA (mRNA) COVID-19 vaccine, died due to myocarditis, according to a study published in the journal Archives of Pathology & Laboratory Medicine on Feb. 14 2022.1 The boys, […]
College Student in New York Dies of Myocarditis Related to Pfizer COVID Shot
A 24-year-old student at Corning Community College in Corning, New York died on Oct. 27, 2021, about six weeks after receiving the second dose of Pfizer/BioNTech’s experimental messenger RNA (mRNA) BNT162b2 (also known as “Comirnaty”) biologic for COVID-19. George Watts Jr., who was healthy and had no underlying medical conditions, was vaccinated in August and […]
Pfizer, BioNTech Seek COVID Biologic Emergency Use Authorization for Infants as Young as Six Months Old
Pfizer and BioNTech have requested emergency use authorization (EUA) for doctors to administer two doses of their mRNA COVID-19 biologic to infants as young as six months old. A statement from Pfizer states that the “rolling submission” application was submitted on Feb. 1, 2022 at the request of the U.S. Food and Drug Administration (FDA) […]
Myocarditis Risk Following mRNA COVID Shots May Be Far Higher Than Previously Estimated
A new study conducted by researchers from the U.S. Centers for Disease Control and Prevention (CDC) and several universities and hospitals in the United States shows that the risk of myocarditis (inflammation of the heart muscle) after receiving a messenger RNA (mRNA) COVID-19 biologic is 133 times greater than the normal risk for the condition […]
Novavax’s Protein COVID-19 Vaccine Now Available in Europe
Novavax’s experimental NVX-CoV2373 (also known as “Nuvaxovid” and “Covovax”) COVID-19 vaccine has been authorized for distribution in the European Union (E.U.), making it the fifth COVID vaccine available for use in the E.U. Approved for people over 18 years old, Nuvaxoid is the first protein subunit COVID vaccine to be approved for use.1 2 The […]
Are Adverse Events in COVID-19 Vaccine Trials Under-Reported?
Phase III controlled trials are considered the ‘gold standard’ for assessing vaccine efficacy and safety in humans. These are the trials upon which authorities have assured the public that COVID-19 vaccines are “safe and effective.” The benefits of the vaccines in reducing disease severity and hospitalizations are well-known, but what do we know about the adverse events?Data on adverse events is vital for effective decision-making by regulators, policy makers, doctors, and patients.